TAK-279 (TYK2 inhibitor) Investor Call on Phase 2b Psoriasis Data
March 19, 2023
Graham Heap
Vice President Global Program Leader, R&D
Andy Plump
President, R&D
Uthra Sundaram
Executive Vice President & Head of Global Product & Launch Strategy, Global Portfolio Division